Peptron, Eli Lilly Evaluated New Diabetes Drug Platform
The companies have completed a feasibility test for a potential once-monthly diabetes treatment.
Updated on Oct. 7, 2026 in Diabetes
Live Poll
Do you trust that collaborative drug development research typically leads to more innovative treatments for patients?
Peptron has finalized a technology evaluation of its SmartDepot drug delivery platform in partnership with Eli Lilly. The collaboration aimed to determine if a GLP-1 peptide-based candidate could be effectively formulated for once-monthly administration.
Why it matters
This evaluation marks a step toward identifying potential long-acting formulations for chronic condition management. The research specifically tested if existing GLP-1 substances could be adapted to reduce dosing frequency for patients.
The joint research project assessed the application of the SmartDepot platform to a GLP-1 peptide substance. The investigation focused on verifying whether the platform could support a once-monthly dosing profile compared to current administration standards.
The players
Peptron
A biotechnology company focused on developing drug delivery platforms and peptide-based therapies.
Eli Lilly
A global pharmaceutical firm that develops a wide range of medications, including prominent therapies for diabetes.
The details
The SmartDepot platform is designed to control the release of therapeutic substances over an extended period. By applying this technology to a GLP-1 peptide-based candidate, the researchers sought to stabilize the medication to allow for significantly less frequent dosing. The process required evaluating how the peptide interacts with the delivery system to ensure consistent release after a single injection.
Timeline
The joint research project between Peptron and Eli Lilly began in October 2025.
The technology evaluation period officially concluded on October 7, 2026.
Health Landscape
The pharmaceutical industry is currently focused on optimizing the delivery of GLP-1 medications to improve long-term adherence. This study represents an effort to move beyond existing dosing schedules by integrating new drug delivery platforms into the standard of care.
This development is a preliminary research milestone and does not impact current treatment options or medication availability. If you are managing diabetes with injectable therapies, continue your current regimen and discuss any questions about future administration schedules with your doctor.
The takeaway
Advancements in drug delivery aim to simplify chronic treatment by extending the time between doses. Patients should monitor major medical news for updates on new treatment delivery methods to discuss with their healthcare providers during routine checkups.
Further reading
For more information on the evolving standards for managing chronic conditions, visit Diabetes.
Live Poll
Do you trust that collaborative drug development research typically leads to more innovative treatments for patients?
